BELITE BIO INC - ADR (BLTE:NASDAQ)
$167.42 2.19 (1.3254%)
Analysed BELITE BIO INC - ADR (BLTE:NASDAQ) News Sources
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
22-04-2026
yahoo.com
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
21-04-2026
yahoo.com
When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?
13-04-2026
yahoo.com
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31-03-2026
yahoo.com
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
10-03-2026
marketbeat.com
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
04-03-2026
yahoo.com
Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success
03-03-2026
yahoo.com
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript
03-03-2026
fool.com
Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
03-03-2026
yahoo.com
Belite Bio Q4 Earnings Call Highlights
02-03-2026
marketbeat.com
What is the current price of BELITE BIO INC - ADR (BLTE:NASDAQ)?
The current price of BELITE BIO INC - ADR (BLTE:NASDAQ) is $167.42.
BELITE BIO INC - ADR (BLTE:NASDAQ) absolute price change since previous trading day?
The absolute price change of BELITE BIO INC - ADR (BLTE:NASDAQ) since the previous trading day is $2.19.
BELITE BIO INC - ADR (BLTE:NASDAQ) percentage price change since previous trading day?
The percentage price change of BELITE BIO INC - ADR (BLTE:NASDAQ) since the previous trading day is 1.3254%.
What is the most recent average sentiment score for BELITE BIO INC - ADR (BLTE:NASDAQ)?
The most recent average sentiment score for BELITE BIO INC - ADR (BLTE:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for BELITE BIO INC - ADR (BLTE:NASDAQ)?
The most recent sentiment for BELITE BIO INC - ADR (BLTE:NASDAQ) is .
SEC-8K** Filing Available For BELITE BIO INC - ADR (BLTE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.